SML3213

Lobaplatin

≥98% (NMR)

• Synonim(y): Cis-[trans-1,2-cyclobutanebis(methylamine)-N,N′]-[(2S)-lactate-O1,O2)-platinum (II), D 19466, D-19466, D19466, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-κN,kN′][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)-platinum, trans-1,2-Cyclobutanedimethanamine, platinum complex
• Wzór empiryczny (zapis Hilla): C₉H₁₈N₂O₃Pt
• Numer CAS: 135558-11-1
• Masa cząsteczkowa: 397.33
• NACRES: NA.77
• UNSPSC Code: 12352107
• Assay: ≥98% (NMR)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (NMR)
• form: powder
• color: white to beige
• solubility: H₂O: 2 mg/mL, clear (Warmed)
• storage temp.: −20°C
• SMILES string: O=C1[O-][Pt+2]2(N[CH2]C3CCC3CN2)[O-]C1C
• InChI: 1S/C6H12N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-8H,1-4H2;2H,1H3,(H,5,6);/q-2;-1;+4/p-1/t;2-;/m.0./s1
• InChI key: HADHSETVEMCBPU-TYOUJGAFSA-M

Opis

Biochem/physiol Actions

Lobaplatin (D-19466) is a third-generation platinum anticancer agent in vitro and in vivo, consisting of ~50:50 mixture of the two trans-1,2-cyclobutanedimethanamine diastereomers in complex with L-lactic acid. Llobaplatin shows antitumor efficacy against various human cancer cancer xenografts and significantly prolongs the survival of mice bearing P388 leukemia (mean life span increase post single i.p. in mg/kg = 46%/4.64 & 77/14.7). Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.

Third-generation platinum anticancer agent in vitro and in vivo.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable